Clinical Trial Update: A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071) [Phase 3]

View source ↗

Summary

Phase 3 comparing once-daily versus twice-daily raltegravir in HIV patients was terminated. Results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Raltegravir (raltegravir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV | Phase 3 | Status: TERMINATED | Results posted: 2012-04-25